Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

JCO Early Release, published online ahead of print Dec 15 2008
Journal of Clinical Oncology, 10.1200/JCO.2008.17.1405
Panos M. Fidias,* Shaker R. Dakhil, Alan P. Lyss, David M. Loesch, David M. Waterhouse, Jane L. Bromund, Ruqin Chen, Maria Hristova-Kazmierski, Joseph Treat, Coleman K. Obasaju, Martin Marciniak, John Gill, and Joan H. Schiller 

From the Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St Louis, MO; Central Indiana Cancer Centers; Eli Lilly & Co, Indianapolis, IN; Oncology Hematology Care, Inc, Cincinnati, OH; and University of Texas Southwestern Medical Center, Dallas, TX.

* To whom correspondence should be addressed. E-mail: pfidias2@partners.org


Purpose: Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced non–small-cell lung cancer (NSCLC). For patients without progression, timing of second-line chemotherapy for optimum clinical benefit remains uncertain. This phase III, randomized trial assessed the efficacy and safety of docetaxel administered either immediately after GC or at disease progression.

Patients and Methods: The chemotherapy-naïve patients enrolled had either stage IIIB NSCLC with pleural effusion or stage IV NSCLC. Gemcitabine (1,000 mg/m2) was administered on days 1 and 8 followed by carboplatin (area under the curve = 5) on day 1. After four 21-day cycles, patients who did not have progression were randomly assigned either to an immediate docetaxel group (docetaxel 75 mg/m2 on day 1 every 21 days, with maximum of six cycles) or to a delayed docetaxel group. The primary end point was overall survival (OS) measured from random assignment. Additional analyses included tumor response, toxicity, progression-free survival (PFS), and quality of life (QOL).

Results: Enrollment totaled 566 patients; 398 patients completed GC; 309 patients were randomly assigned equally to the two docetaxel treatment groups. Toxicity profiles were generally comparable for the docetaxel groups. Median PFS for immediate docetaxel (5.7 months) was significantly greater (P = .0001) than for delayed docetaxel (2.7 months). Median OS for immediate docetaxel (12.3 months) was greater than for delayed docetaxel (9.7 months), but the difference was not statistically significant (P = .0853). QOL results were not statistically different (P = .76) between docetaxel groups.

Conclusion: We observed a statistically significant improvement in PFS and a nonstatistically significant increase in OS when docetaxel was administered immediately after front-line GC, without increasing toxicity or decreasing QOL.

About
JCO Editorial
Roster Adver